EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Klf9 Loss of Function Protects Against Glucocorticoids Induced Skeletal Muscle Wasting

Yujie Zhang, Jingran Hao, Yueyao Feng, Tongtong Qiu, Jinjin Wu, Xuenan Zhou, Heng Fan, Yongsheng Chang iD

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.70020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Yujie Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory of Cellular Homeostasis and Disease, Department…. Hauptthemen laut MEDLINE: Kruppel-Like Transcription Factors, Muscular Atrophy, Muscle, Skeletal, Glucocorticoids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Basic Research Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucocorticoids (GCs) are the most important and frequently used class of anti‐inflammatory drugs. However, the mechanisms underlying excessive glucocorticoid‐mediated induction of muscle atrophy remain incompletely understood.

Methods

We generated skeletal muscle‐specific Klf9 transgenic mice (m Klf9 TG) and skeletal muscle‐specific Klf9 knockout mice ( Klf9 mlc−/− ). The body weight, tissue weight, body composition, grip strength, running distance and muscle fibre cross section of m Klf9 TG, Klf9 mlc−/− mice and their littermate controls were examined. Expression of genes related to muscle protein synthesis and degradation pathways were also tested in the m Klf9 TG mice, Klf9 mlc−/− mice and their littermate controls. We performed Klf9 gain‐ or loss‐of‐function studies in differentiated C2C12 myotubes using lentiviruses encoding Klf9 or the shRNA specific to Klf9 in vitro. Luciferase reporter gene assay and ChIP assay were performed to explore the molecular mechanism of Klf9 action. Klf9 mlc−/− and Klf9 fl/fl mice were treated with dexamethasone (Dex). Multiple genetic and pharmacological approaches were also used to investigate the intracellular signalling cascades underlying the Dex/Klf9‐ediated skeletal muscle wasting.

Results

Skeletal muscle Klf9 gene expression was significantly upregulated by Dex ( p < 0.05 or p < 0.01 vs. vehicle group). Compared with littermate control mice (R‐loxP), m Klf9 TG mice exhibited decreased skeletal muscle mass (TA 0.101 ± 0.018 vs. 0.040 ± 0.007 g, p < 0.001) and impaired grip strength (forelimb 157.4 ± 3.7 vs. 93.45 ± 9.8 and four limbs 255.3 ± 23.1 vs. 170.1 ± 36.2, p < 0.001). Conversely, compared with Klf9 fl/fl , Klf9 mlc−/− mice exhibited increased skeletal muscle mass (TA 0.103 ± 0.012 vs. 0.123 ± 0.005 g, p < 0.001) and enhanced grip strength (forelimb 110.3 ± 5.8 vs. 156.8 ± 10.0 and four limbs 155.5 ± 6.3 vs. 226.5 ± 19.7, p < 0.001). Skeletal muscle Klf9 deficiency alleviated muscle atrophy induced by acute high‐dose Dex treatment ( p < 0.001). Mechanistically, Klf9 induces the expression of myostatin (Mstn) and muscle atrophy F‐box (MAFbx) by directly binding to and activating the transcription of their promoters. Treatment of AAV‐MSTN reduced the increased grip strength of Klf9 mlc−/− mice (forelimb 143.5 ± 22.3 vs. 118.8 ± 3.1 and four limbs 249.8 ± 24.7 vs. 208.7 ± 9.0, p < 0.001).

Conclusions

In summary, our study provides novel insights into the mechanisms underlying GC‐induced muscular atrophy and reveals that skeletal muscle induction of Klf9 expression is a mechanism underlying GC therapy‐induced muscle loss. Thus, targeting Klf9 may offer novel approaches to the treatment of skeletal muscle wasting diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kruppel-Like Transcription FactorsMuscular AtrophyMuscle, SkeletalGlucocorticoidsAnimalsMiceMice, KnockoutDexamethasoneMice, TransgenicMale

Stichwörter der Autor:innen

Krüppel‐like factor 9glucocorticoidsmuscle atrophymyostatin

Substanzen

Kruppel-Like Transcription FactorsGlucocorticoidsKlf9 protein, mouseDexamethasone

Autor:innen und Institutionen

  • Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Tianjin Key Laboratory of Cellular Homeostasis and Disease, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianji…
  • Department of Reproductive Medicine, General Hospital of Ningxia Medical University (The First Clinical Medical College of Ningxia Medical University), Yinchuan, China.
  • Ningxia Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China.

ORCID-Profile: Yongsheng Chang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • National Basic Research Program of China

Zitieren

APA

Zhang, Y., Hao, J., Feng, Y., Qiu, T., Wu, J., Zhou, X., Fan, H., & Chang, Y. (2025). Klf9 Loss of Function Protects Against Glucocorticoids Induced Skeletal Muscle Wasting. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70020

Vancouver

Zhang Y, Hao J, Feng Y, Qiu T, Wu J, Zhou X, et al. Klf9 Loss of Function Protects Against Glucocorticoids Induced Skeletal Muscle Wasting. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.70020

BibTeX
@article{Zhang2025,
  author = {Zhang, Yujie and Hao, Jingran and Feng, Yueyao and Qiu, Tongtong and Wu, Jinjin and Zhou, Xuenan and Fan, Heng and Chang, Yongsheng},
  title = {Klf9 Loss of Function Protects Against Glucocorticoids Induced Skeletal Muscle Wasting},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.70020}
}
Kostenlos starten →